CLPT ClearPoint Neuro, Inc.

CIK 0001285550 24 ready 8-Ks latest May 21, 2026, 4:30 PM ET RSS · JSON

Activity: NORMAL 2 filings / 30d vs 1 baseline

Ready 8-Ks 24

Latest filing May 21, 2026, 4:30 PM ET

Top materiality 0.80

Event mix earnings ×11 · other_material ×6 · m_and_a ×3

Sentiment 15 pos · 2 neg · 7 neu

Latest earnings ▼ miss 2026-Q1

Recent 8-K filings for CLPT

Highest-materiality recent filing

ClearPoint Neuro secures up to $110M from Oberland Capital with $33.5M funded at closing

May 12, 2025, 7:59 PM ET debt materiality 0.80 positive item 1.01 item 8.01 item 9.01

Enters note agreement for up to $105M; $30M funded at closing, up to $25M optional second tranche, up to $50M third tranche.
Issues 275,808 shares at $12.69 in registered direct offering for $3.5M gross proceeds.

Read filing →

May 21, 2026, 4:30 PM ET other material materiality 0.55 neutral item 5.02 item 5.07 item 9.01

ClearPoint Neuro shareholders approve 1M share increase in 2013 incentive plan; board committees reappointed

Shareholders approved 7th Amended 2013 Incentive Compensation Plan, increasing share pool by 1,000,000 shares to 7,806,250 total.
May 13, 2026, 4:05 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

ClearPoint Neuro Q1 revenue $12.1M (+43% YoY); guides FY2026 $52-56M

Record Q1 revenue of $12.1M; organic device growth 25% YoY; gross margin expanded to 64% from 60%.
March 17, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

ClearPoint Neuro reports Q4 revenue $10.4M (+34% YoY); FY 2025 revenue $37.0M (+18%); guides FY 2026 $52-56M

Q4 2025 revenue $10.4M including $1.2M from recent IRRAS acquisition; organic growth 19% YoY.
February 5, 2026, 6:59 PM ET M&A materiality 0.55 negative item 9.01

ClearPoint Neuro files financials for acquired IRRAS; IRRAS cash from ops -$11.4M in 2024

IRRAS 2024 operating cash outflow $11.4M; accumulated deficit $105.3M.
January 12, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

ClearPoint Neuro Q4 2025 prelim revenue $10.4M (+20% YoY); FY2026 guidance $54-60M

Q4 2025 preliminary unaudited revenue ~$10.4M, 20% comparable sales growth over Q4 2024, excluding recent IRRA flow acquisition.
January 5, 2026, 6:59 PM ET debt materiality 0.15 neutral item 1.01 item 2.03 ◈ Material Agreements

ClearPoint Neuro enters consent for Swedish subsidiary reorganization under note purchase agreement

Consent dated Dec 29, 2025 with TPC Investments III LP (Oberland affiliate) under the May 12, 2025 Note Purchase Agreement.
November 20, 2025, 6:59 PM ET M&A materiality 0.70 positive item 1.01 item 2.01 item 3.02 item 7.01 item 9.01 ◈ M&A Transactions

ClearPoint Neuro completes acquisition of IRRAS for $5M cash + 1.325M shares

Acquisition closed Nov 20, 2025; IRRAS shareholders received $5M cash and 1.325M CLPT shares.
November 6, 2025, 6:59 PM ET M&A materiality 0.70 positive item 1.01 item 7.01 item 9.01

ClearPoint Neuro to acquire IRRAS for $5M cash + 1.325M shares; combined 2026 rev $54-60M

Total consideration: $5M cash plus 1.325M ClearPoint shares; earnout of 25% of net IRRA flow sales above thresholds.
November 6, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

ClearPoint Neuro Q3 rev $8.9M (+9% YoY); narrows FY25 guide $36-38M; acquires IRRAS

Q3 revenue $8.9M, up 9% YoY; cash $38.2M as of Sept 30, 2025.
August 12, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

ClearPoint Neuro Q2 revenue record $9.2M (+17% YoY); secures up to $105M note financing

Record Q2 revenue $9.2M, up 17% YoY; neurosurgery segment revenue up 33% to $3.4M.
June 17, 2025, 7:59 PM ET other material materiality 0.45 neutral item 1.01 item 9.01

ClearPoint Neuro signs 132-month lease for ~30,171 sq ft in San Diego life science building

Lease with BRE-BMR SCD LLC for office, R&D, and lab space at $5.95/sq ft initial monthly base rent.
May 23, 2025, 7:59 PM ET other material materiality 0.25 neutral item 5.02 item 5.07 item 9.01

ClearPoint Neuro stockholders approve all six proposals at 2025 annual meeting

All eight director nominees elected; Joseph M. Burnett received 9,980,965 votes for.
May 19, 2025, 7:59 PM ET other material materiality 0.15 neutral item 8.01 item 9.01

ClearPoint Neuro amends director compensation plan with updated cash retainers

Board chair annual retainer increased to $75,000; other members to $45,000 (effective July 1, 2025).
May 13, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01

ClearPoint Neuro reports record Q1 revenue $8.5M, consumables up 104% YoY

Q1 revenue $8.5M (record), up 11% YoY; consumable product revenue grew 104% to $5.5M.
May 12, 2025, 7:59 PM ET debt materiality 0.80 positive item 1.01 item 8.01 item 9.01

ClearPoint Neuro secures up to $110M from Oberland Capital with $33.5M funded at closing

Enters note agreement for up to $105M; $30M funded at closing, up to $25M optional second tranche, up to $50M third tranche.
February 26, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

ClearPoint Neuro reports record FY2024 revenue $31.4M, 31% growth; guides FY2025 $36-41M

FY 2024 revenue $31.4M (+31% YoY); Q4 revenue $7.8M (+14% YoY).
November 7, 2024, 6:59 PM ET other material materiality 0.65 negative item 1.01 item 9.01

ClearPoint Neuro enters $50M ATM equity offering with Stifel

ATM agreement with Stifel allows sale of up to $50M in common stock from time to time.
November 7, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

ClearPoint Neuro Q3 revenue $8.1M (+41% YoY); FY guidance reaffirmed

Record quarterly revenue of $8.1M, up 41% YoY; navigation & device revenue $2.9M (+49%).
August 26, 2024, 7:59 PM ET debt materiality 0.55 positive item 7.01 item 9.01

ClearPoint Neuro repays $10M convertible note early, eliminates all debt

On Aug 23, 2024, fully repaid $10M convertible note held by PTC Therapeutics (orig. maturity Jan 2025).
August 7, 2024, 7:59 PM ET earnings materiality 0.78 positive item 2.02 item 7.01 item 9.01

ClearPoint Neuro Q2 revenue $7.9M (+32% YoY); raises FY2024 guidance to $30-33M

Record quarterly revenue of $7.9M, up 32% YoY; product revenue more than doubled to $4.9M.
May 16, 2024, 7:59 PM ET other materiality 0.20 neutral item 5.02 item 5.07 item 9.01 ◈ Shareholder Votes ×4

ClearPoint Neuro stockholders re-elect eight directors, approve incentive plan

All eight director nominees elected with over 11.6M votes for each; broker non-votes 6.8M.
May 7, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

ClearPoint Neuro Q1 revenue $7.6M (+41% YoY); biologics revenue $4.3M (+61%); cash burn down 32%

Record quarterly revenue of $7.6M, up 41% YoY; biologics/drug delivery revenue up 61% to $4.3M.
March 12, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases ×2

ClearPoint Neuro Q4 revenue $6.8M (+32% YoY); FY2023 revenue $24M (+17%); reaffirms 2024 guidance $28M-$32M

Q4 2023 revenue $6.8M, up 32% YoY; full-year revenue $24.0M, up 17% YoY.
March 1, 2024, 6:59 PM ET other material materiality 0.65 neutral item 1.01 item 9.01

ClearPoint Neuro prices $15M public offering of 2.3M shares at $6.50

Offering of 2,307,694 shares of common stock at $6.50 per share; underwriters have 30-day option for 346,154 additional shares.

Earnings & guidance

2026-Q1 EPS reported -$0.32 vs consensus -$0.27 ▼ miss (-20.7%) filing →

Materiality & sentiment trend

Max materiality 0.80 · Median 0.70 · Most common event earnings

15 positive 2 negative 7 neutral

source · CLPT on sec.gov